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Objective: to investigate if serum lipoprotein (a) level is a predictor of survival in patients with lower limb atherosclerotic
occlusive disease.
Design: prospective follow up study.
Methods: demographic, biochemical and disease variables were collected prospectively in 441 patients with lower limb
arterial occlusive disease. Survival data were obtained at a mean follow up of 44 months, and significant risk factors
identified by the life table method and multivariate Cox regression analysis.
Results: the cumulative survival for all patients at three and five years was 79% and 63%. Lipoprotein (a) level was the
only significant independent biochemical predictor for all deaths and cardiorespiratory deaths on multivariate analysis,
along with age, diabetes mellitus, renal impairment, cardiac diseases and major amputation. An elevated Lipoprotein(a)
level of >24 mg/dl incurred a 107% and 45% increase in mortality at three and five years respectively. The higher
mortality associated with elevated Lipoprotein (a) was particularly evident in patients with critical ischemia, in whom
three and five year survival was reduced from 85% to 63% and 67% to 53% (p=0.0064). In claudicants a survival
discrepancy was manifested only after five years (73% vs 62%), and the overall association did not reach statistic
significance (p=0.52).
Conclusions: lipoprotein (a) level is a reliable biochemical marker for survival in patients with critical ischemia where
traditional atherosclerosis risk factors were prevalent.
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Introduction significantly higher in Chinese patients with lower
limb ischaemia than healthy age and sex matched
Patients with chronic lower limb ischaemia have a controls.3 Patients with a Lp(a) level exceeding 24 mg/
dl incurred a two-fold increase in risk of PVD andreduced long term survival.1,2
Lipoprotein (a) (Lp(a)) is a heterogenous glyco- have a significantly higher incidence of critical limb
ischaemia.protein with a LDL-like core attached by disulfide
bonds to apolipoprotein (a) which has a structural The level of Lp(a) is genetically determined and
remains relatively constant and unaffected by age orhomology to plasminogen. Serum level of Lp(a) is
associated with coronary and peripheral artery disease, traditional lipid lowering therapy. This study aims to
determine if serum lipoprotein (a) level is an in-renal failure, and recurrence after coronary an-
gioplasty. The exact pathogenetic mechanism of Lp(a) dependent prognostic indicator for survival in patients
with lower limb arterial insufficiency.and atherogenesis has not yet been established, al-
though lipoprotein-oxidative endothelial damage,
competitive binding with plasminogen receptors, and Patients and Methods
inhibition of fibrin-dependent activation of plas-
minogen have been suggested. The study was initiated in 1991 as a prospective,
There is also evidence that elevated Lp(a) is as- observational study.
sociated with peripheral vascular disease.3–6 In a pre-
vious study median fasting Lp(a) level was
Patients
∗ Please address all correspondence to: S. W. K. Cheng, Division of
Vascular Surgery, Department of Surgery, The University of Hong A total of 441 consecutive patients who consentedKong Medical Centre, Queen Mary Hospital, Pokfulam Road, Hong
Kong, China. to blood testing was recruited into the study. These
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Table 1. Patient demographic and biochemical characteristics (n=441).
Patient demographics Claudicants Critical ischaemia p
(n=210) (n=231)
Male gender 155 (74) 133 (58) <0.001
Age 67 70 NS
Body weight (kg) 59 53 NS
Smoking 149 (71) 148 (64) NS
Hypertension 126 (60) 142 (62) NS
Diabetes mellitus 86 (41) 111 (48) NS
Hyperlipidaemia 98 (47) 96 (42) NS
Ischaemic heart disease 69 (33) 75 (33) NS
Chronic respiratory disease 20 (10) 52 (23) 0.014
Renal disease 47 (22) 65 (28) NS
Main disease distribution
Aortoiliac 65 (31) 42 (18) <0.001
Femoro-popliteal 145 (69) 189 (82) <0.001
Major amputation 6 (3) 55 (24) <0.001
Biochemical characteristics Claudicants Critical ischaemia p
(Mean±standard deviation) (n=210) (n=231)
Fasting glucose (mmol/l) 6.8±2.8 6.7±3.0 NS
Cholesterol (mmol/l) 5.7±1.3 5.4±1.4 NS
LDL (mmol/l) 3.8±1.2 3.6±1.1 NS
HDL (mmol/l) 1.1±0.4 1.1±0.4 NS
VLDL (mmol/l) 0.9±0.6 0.7±0.4 <0.001
Triglyceride (mmol/l) 1.8±1.1 1.6±0.9 0.009
Apolipoprotein A1 (mg/dl) 136±37 130±43 NS
Apolipoprotein B (g/dl) 121±32 115±30 NS
Lipoprotein (a) (mg/dl) 36±32 42±36 NS
Number in parentheses indicated percentage.
NS=not significant (p>0.05).
LDL=Low density lipoprotein, HDL=High density lipoprotein, VLDL=Very low density lipoprotein.
consisted of 288 men and 153 women, with a mean exceeding 24 mg/dl was regarded to have elevated
Lp(a), whereas those with levels of Ζ24 mg/dl be-age of 69±9 years (range 37–87 years). All patients
were interviewed and examined by a vascular surgeon longed to the low Lp(a) category.
All patients were followed up regularly in a ded-and investigated in a non-invasive vascular laboratory.
The disease characteristics were graded according to icated vascular clinic. Mortality data were directly
obtained from readmission, or in case of patients whothe reporting standards specified by the Society of
Vascular Surgery/International Society for Cardio- defaulted follow up, by telephone interviews and from
hospital computer registry. The relationship of survivalvascular Surgery (SVS/ISCVS) using clinical and vas-
cular laboratory criteria.7 Their demographic data and to Lp(a) and other confounding risk factors were ex-
amined.disease characteristics were recorded in a com-
puterised registry. A fasting blood sample was ob- Demographic variables analysed included gender,
age, body weight, smoking, hypertension, diabetestained and standard biochemical and lipid studies
were performed (Table 1). Lp(a) level was determined mellitus, hyperlipidaemia (as defined by SVS/
ISCVS Reporting Standards),7 history of cardiac,by antiserum-antibody reactions using immuno-
turbidometric assay (Incstar corporation, Stillwater, respiratory (pulmonary function tests <80% pre-
dicted), and renal diseases (serum creatinineMinnesota, U.S.A.).8
The patients were classified according to their symp- >120 mol/l or clearance <50 ml/min). Biochemical
risk factors evaluated were fasting glucose, serumtom of presentation into two groups of claudication
(n=210) or critical ischemia (n=231). The claudicants cholesterol, low density lipoprotein (LDL), high
density lipoprotein (HDL), very low density lipo-consisted of 42, 93, and 75 patients respectively in SVS
category 1–3, while 166 patients had tissue loss. A protein (VLDL), and triglycerides, and Apolipo-
protein A1 and B, and lipoprotein (a). DiseaseLp(a) level of 24 mg/dl identified in a previous case-
control study in our population was chosen as the variables examined included disease site (aortoiliac
vs femoro-popliteal), severity (SVS/ISCVS cat-reference value.3 Patients with a serum Lp(a) levels
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egory), and presentation (claudicants vs critical
ischaemia), and the need of major amputation.
Factor analysis and statistical methods
The patient survival data were presented and analysed
using the life table method. Demographic, biochemical
and disease risk factors were first correlated with
survival and also with Lp(a) levels using univariate
methods and the Pearson coefficient. Mortality data
was analysed with respect to the specified variables to
determine their predictive value. Survival comparisons
was examined using the generalized Wilcoxon (Gehan)
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Fig. 1. Life table representations of mortality of 441 patients withanalysis for continuous variables. In order to examine
atherosclerotic peripheral arterial occlusive disease by life table
the possible interrelationship between risk factors, sig- representation, categorised by lipoprotein (a) level.
nificant univariate factors were entered into a multi-
variate Cox regression proportional hazards model to
age. The mean age of the High Lp(a) group was 69±9identify independent determinants affecting long term
years; that of the Low Lp(a) group 68±8 years (p=survival and their relative risks adjusted for the effects
0.5).of all other confounding variables. A variable is entered
Lp (a) distribution had no association with gender,if the significance level is less than the entry value of
age, and co-morbidities. Lp(a) levels correlated posi-0.05, and removed if the significance level is greater
tively with disease category, renal impairment, cho-than 0.10. Mortality was expressed both as all deaths
lesterol, LDL, and apolipoprotein levels, andas well as cardiac and respiratory deaths.
negatively with fasting glucose and VLDL.
Results
Survival and follow up
Patients and disease characteristics
The patients were followed up every three to six
Of the 441 patients 210 (48%) presented with in- months for a mean follow up time of 44±27 months
termittent claudication, and 231 (52%) with critical (range 6 months to 9.6 years). During follow up 144
ischaemia. The demographic and biochemical data are patients died (33%), 53 of 210 (25%) claudicants, and
expressed in Table 1. There was a slightly higher 91 of 231 (39%) patients with critical ischaemia. Cardio-
proportion of male patients in the claudicants (74%) vascular and respiratory diseases accounted for 47%
than those with critical ischaemia (58%). The majority (67 patients) of all deaths. The cumulative survival for
suffered from femoro-popliteal segment disease, more all patients at one, three and five years were 94%, 79%,
so in the critical ischemia group (82% vs 69% in and 63% respectively (standard error of 0.01, 0.02, and
claudicants). There were no significant differences in 0.03). Their median survival was 81.5 months (Fig. 1).
the mean age of patients between claudicants and
patients with critical ischaemia. In general the two
groups do not differ in their co-morbidities and lipid
Risk factors for survivaland biochemical risk factors. The critical ischemia
group has a slightly higher mean serum Lp (a) level
The significant factors affecting survival on univariatethan the claudicants (42.3 vs 36.3 mmol/l), but the
analysis were listed in Table 2. On multivariate coxdifference was not statistically significant.
regression analysis, only the patient’s age, diabetes,
renal impairment and cardiac diseases, lipoprotein
(a) level, and major amputation were identified asLipoprotein (a) distribution
independent risk factors predicting patient survival
(Table 3). All other lipid and biochemical variablesA total of 177 patients (40%) had Lp(a) levels of 24 mg/
dl or lower, whereas 264 patients (60%) had elevated were not found to be significant determinants of mor-
tality.Lp(a) levels. Again the two groups are comparable in
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Table 2. Significant variables affecting mortality in patients with
atherosclerotic lower limb occlusive disease on univariate analysis.
Clinical variables p value
Gender (female) 0.039
Age (years) 0.005
Smoking <0.001
Hypertension 0.045
Heart disease 0.027
Respiratory disease 0.005
Renal disease <0.001
Diabetes 0.05
Cerebrovascular disease <0.001
Disease category (critical ischaemia) 0.002
Amputation 0.016
Biochemical variables
Cholesterol 0.049
Triglyceride 0.005
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VLDL 0.022
Lipoprotein (a) 0.001 Fig. 2. Survival of 210 claudicants categorised by lipoprotein (a)
level.
An elevated Lp(a) level of >24 mg/dl was de-
termined as a significant detrimental risk factor to
survival (p=0.0018) (Fig. 1), and was associated with
a 107% and 45% increase in mortality over three and
five years respectively. A high level of Lp(a) was
associated with a distinctly higher mortality in patients
with critical ischemia, with three and five year survival
reduced from 85% to 63% and 67% to 53% respectively
(p=0.0064). The mortality rates for high and low Lp(a)
groups were 146.8 and 85.8 deaths per 1000 patient-
years of follow up respectively, giving a relative risk
of 1.7. In claudicants a high Lp(a) level also conferred
a survival disadvantage, but the initial difference was
small. A survival discrepancy was only demonstrated 0 120
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after five years of follow up (73% vs 62%), and the
overall association did not reach statistical significance Fig. 3. Survival of 231 patients with critical ischaemia, categorised
by lipoprotein (a) level.(p=0.52). The mortality rates for claudicants with a
high and low Lp(a) were 69.5 and 59.2 deaths per 1000
years (relative risk of 1.2). The cumulative survival Discussion
data of the various categories of patients are listed in
Table 4 and displayed in Figures 2 and 3. Lp(a) is also High Lipoprotein (a) level is a powerful predictor of
coronary artery disease,9 premature myocardial in-a significant predictor of mortality when cardiac and
respiratory deaths were analysed independently (p= farction, and stroke,10 especially in the presence of other
risk factors such as elevated LDL. The distribution of0.004).
Table 3. Significant independent variables predicting patient survival, multivariate
Cox regression analysis.
Variable p Odds ratio 95% confidence
Exp (B) interval
Age 0.000 1.06 1.04–1.09
Renal disease 0.000 2.20 1.52–3.18
Cardiac disease 0.047 1.46 1.01–2.12
Diabetes mellitus 0.019 1.55 1.08–2.25
Lipoprotein (a) 0.007 1.01 1.01–1.02
Amputation 0.001 2.26 0.29–0.67
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Table 4. Lipoprotein (a) and patient survival by life table method.
Lp(a) n 3 year 5 year Medial p value
level cumulative cumulative survival
(mg/dl) survival survival (months)
All patients All 441 79% 63% 82 —
Ζ24 177 86% 70% 86 0.002
>24 264 71% 57% 72
Claudicants Ζ24 98 87% 73% 110+ 0.525
>24 112 89% 62% 90
Critical ischaemia Ζ24 79 85% 67% 84 0.006
>24 152 63% 53% 62
Lp(a) is skewed and population specific, and the level pain and tissue loss was only 31%.18 The main causes
of death in our study population remained cardiacof Lp(a) as well as the frequency of Lp(a) elevation
also varies with race. The serum concentration of Lp(a) and respiratory, those with critical ischaemia having
a worsened prognosis. In the Cox regression analysis,is believed to be genetically determined and controlled
by the apolipoprotein (a) gene locus which governs a it is not surprising that age, and co-morbidities like
renal impairment, cardiac diseases, diabetes mellitus,size polymorphism. The level of Lp(a) remains rel-
atively constant and largely unaffected by age, other and amputation, were also significant determinants of
mortality. The traditional vascular risk factors as-classical vascular risk factors, or pharmacological in-
terventions.9 sociated with poor survival in the general population,
such as smoking, hyperlipidaemia and hypertensionA high level of Lp(a) was shown to be a predictor for
cardiac death in patients with symptomatic myocardial were not found to be significant mortality predictors
in this group of patients in whom these factors areinfarction and angina,11 and also prognosticated major
coronary events and total mortality in patients with prevalent. Lp(a) may be a useful discriminatory marker
for survival in these high risk patients. As the manycoronary heart disease.12 However other studies failed
to demonstrate an association with late cardiac deaths factors predicting survival could be inter-related, it is
also possible that Lp(a) carries with it a very powerfulafter coronary artery bypass surgery.13 Evidence of a
relationship of Lp(a) and survival was revealed in a association with cardiovascular death, such that the
effects of other factors on mortality, such as a history ofstudy of diabetes patients, where a low concentration
was found to be associated with long disease dur- heart disease and stroke, were masked on multivariate
analysis.ation.14 The predictive value of Lp(a) as a marker for
long term survival in patients with atherosclerotic With coronary angioplasty and stenting, there has
yet to be convincing evidence to establish whether aperipheral vascular disease has not yet been de-
termined. high Lp(a) level will lead to a higher incidence of
thrombotic events and restenosis,19 although one studyWe have identified Lp(a) as an independent pre-
dictor for total death and cardio-respiratory deaths in did suggest an association of Lp(a) levels of >50 mg/
dl with a higher incidence of occlusive complicationspatients with critical lower limb ischemia. It is possible
that Lp(a) forecasts the eventual occurrence of fatal after vascular and endovascular procedures.20
Although we have shown that Lp(a) level is a usefulcoronary and cerebrovascular events at a terminal
phase of generalised atherosclerosis. Whereas in the predictor of mortality in patients with critical lower
limb ischaemia, it remains to be determined whethercritical ischemia group the relationship to mortality
was clearly demonstrated, the effect of Lp(a) on mor- Lp(a) serves merely as a marker for advanced athero-
sclerosis and mortality, or whether it has a directtality in the claudicants may only be manifested after
a longer period of follow up, as their atherosclerotic contribution to disease and death. It is also not known
whether modification of Lp(a) levels may affect sur-disease is at an earlier stage.
Peripheral arterial disease is an indicator for gen- vival. Current efforts to modify Lp(a) concentration
with drugs such as niacin were not met with mucheralised atherosclerosis. Patients with peripheral vas-
cular disease, particular those with critical ischaemia, success due to the high dosage required and un-
acceptable side effects. There is some evidence thatare associated with a higher mortality than the general
population;1,2,15 the leading causes of death being cor- Lp(a) interacts with lipid and other nonlipid risk fac-
tors resulting in an exaggerated risk of coronary arteryonary and cerebrovascular diseases.16,17 A 10-year fol-
low up study of patients with critical ischemia showed disease.21 Since we aimed to study survival in a group
of patients with traditional vascular risk factors, andthat the overall five year survival of patients with rest
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